The 4th Annual “Induced Pluripotent Stem Cells: Production and Utility in Regenerative Medicine and Other Applications " Event

www.regonline.co.uk/IPS2013

The Royal College of Pathologists, Carlton House Terrace, London, SW1Y 5AF, United Kingdom

Tuesday, 04 June 2013

This 4th Annual event will review the drawback and advantages of hIPSCs for diverse type of clinical applications.

This event has CPD accreditation

This event is part of the 2013 Euroscicon Stem Cell Trilogy. To find out more see www.stemcells2013.com

Meeting chair
Dr Lyn Healy, NIBSCC, South Mimms, UK

9:00 – 9:45 Registration

9:45 – 10:00 Introduction by the Chairs: Dr Lyn Healy, NIBSCC, South Mimms, UK

10:00 – 10:40 Deriving Metabolically Active Hepatocytes from Pluripotent Stem Cells
Dr David Hay, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland

Faithfully recapitulating human physiology “in a dish” from a renewable source remains a holy grail for medicine and pharma. Many procedures have been described that, to a limited extent, exhibit human tissue specific function in vitro. In particular, incomplete cellular differentiation and/or the loss of cell phenotype post-differentiation play a major part in this void. We have developed an interdisciplinary approach to address this problem, employing skill sets in cell biology, materials chemistry and pharmacology. Pluripotent stem cells were differentiated to hepatocytes before being re-plated onto a synthetic surface. Our approach yielded metabolically active hepatocyte populations that displayed stable function for over two weeks in vitro. Although metabolic activity was an important indication of cell utility, the accurate prediction of cellular toxicity in response to specific pharmacological compounds represented our goal. Therefore, detailed analysis of hepatocellular toxicity was performed in response to well defined compounds and compared to primary human hepatocytes. Importantly, stem cell derived hepatocytes displayed equivalence to primary human material. Moreover, we demonstrated that our approach was capable of modelling metabolic differences frequently observed in the population.

10:40 – 11:20 Biophysical considerations of differentiation and reprogramming in embryonic stem cells

Dr Kevin Chalut, University of Cambridge, United Kingdom

11:20 – 11:50 Speakers’ photo then mid-morning break and trade show

11:50 – 12:30 Surround yourself with support – showcasing services and products from Life Technologies™

Dr Roland Leathers, Life Technologies, UK

This session will showcase the services and products that are available to you to support your stem cell research. We will also include a recent example where we have worked directly with the Parkinson’s Institute to generate iPSC from patients. In collaboration we utilised several technologies including semi-conductor sequencing to characterise these patient cell lines.

12:30 – 13:10 Stemming Visual Loss Using Pluripotent Stem Cells
Professor Pete Coffey, Head of Ocular Biology & Therapeutics, UCL Institute of Ophthalmology, London, UK
The London Project to Cure Blindness was launched at the UCL Institute of Ophthalmology in June 2007, and aims to make the most of human embryonic stem cells to prevent blindness and restore sight in patients with Age-related Macular Degeneration (AMD) by 2013. Our goal is to replace cells essential for “seeing” lost by disease at the back of the eye. We aim to repair and regenerate the aged diseased eye using human embryonic stem cells which have been transformed into the cells affected in AMD: the support cells for the photoreceptors (retinal pigment epithelium) and the photoreceptors. The cells will be surgically implanted into a clinical population of AMD patients.

13:10 – 14:10 Lunch and trade show

Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you

14:10– 14:50 Using iPS cells to model embryo development

Dr Ramiro Alberio, University of Nottingham, UK

The development of new cellular reprogramming technologies has enabled the reversal of differentiation of somatic cells into undifferentiated cells. Modulation of the signalling pathways as well as selection of specific exogenous factors for iPS production can lead to the generation of cells with different pluripotent characteristics that can be used to recapitulate normal embryo development in vitro. Our laboratory is using the new understanding on metastable states of pluripotency to model the developmental transitions during embryo development and exploit this features to generate animal cells amenable able to contribute efficiently to germline chimeras.

Our studies are focused in the differentiation of pluripotent cells into germ cell precursors in different species. Elucidating the program of germ cell differentiation is of critical importance for developing safe technologies that will enable the generation of artificial gametes.

14:50 – 16:00 Question and Answer Session

Delegates will be asked to submit questions to a panel of experts. Questions can be submitted before the event or on the day

16: 00 - 16:30 Chairman’s summing up

About the Speakers

Dr David Hay is a Principal Investigator at the University of Edinburgh’s MRC Centre for Regenerative Medicine. David has worked in the field of stem cell biology and differentiation over the last decade. David’s work has highlighted the important role that cell physiology and chemical biology plays in the generation of predictive and drug inducible human hepatocytes from pluripotent stem cells. The impact of this work has led to a number of publications and regular appearances at high profile international conferences. Most recently David and his colleagues spun out a company from the University of Edinburgh, FibromEd, whose focus is to reduce the cost of human drug attrition.

Roland Leathers finished his PhD in cell and molecular biology at the University of Sheffield University, UK in 1989. Following a post-doc in Sheffield, he moved to the Ecole Polytechnique Federale de Lausanne (EPFL) in Switzerland to lead an industrial research collaboration with Hoffmann La Roche. Roland joined Life Technologies in 1993 and has since occupied various positions within the organization. He is currently Strategic Alliances Manager for the Stem Cell and Drug Discovery business unit with geographical responsibility across Europe, India and Australasia.

Ramiro Alberio is a Lecturer in Developmental Epigenetics at the University of Nottingham, UK. Research in his laboratory focuses in developing cellular reprogramming technologies, and in the study of pluripotency in different mammalian species. The laboratory uses stem cells from mouse, human and pig to determine the common pathways used by pluripotent cells. This knowledge is used to design protocols for iPS generation, and to study their differentiation potential in vivo and in vitro. He is co-founder of EvoCell Ltd., a University spin-off company that commercializes stem cell technologies developed in his laboratory.
Keywords: iPSC, hepatocyte, liver, CYP p450, translation, supply chain, delivery, GMP, manufacturing,drug, pluripotent stem cell, hepatocyte, pancreas, liver; beta-cell, Stable Karyoytpe, High-throughput efficiency, Embryonic Stem cells, Induced pluripotency, Nanog, neural stem cell, glioblastoma, DNA methylation, reprogramming, iPS cells, reprogramming, Pluripotentcy, STEMCCA, ESGRO 2i, Pluripotency; reprogramming; chromatin signatures; DNA replication timing; histone acetyltransferase p30, hESC, Drug Metabolism, Hepatocyte, Liver, reprogramming, characterisation, Parkinsons, culture

Event Web Site: www.regonline.co.uk/IPS2013

Post expires at 11:36am on Monday June 3rd, 2013

Bookmark It